InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and Kenya Medical Research Institute Partner on Phase I Trial for Mpox and Smallpox Vaccine TNX-801
Tonix Pharmaceuticals (NASDAQ: TNXP) has entered a research agreement with the Kenya Medical Research Institute (KEMRI) to initiate a Phase I clinical study of its TNX-801 vaccine candidate in Kenya. The study will evaluate the safety, tolerability, and immunogenicity of TNX-801, a horsepox-based live virus vaccine designed to protect against mpox and smallpox. Tonix will sponsor the trial, while KEMRI will oversee its execution. This…